Management of candidemia and invasive candidiasis

被引：5

作者：

Taieb, F. ^{[1
,2
]}

Mechai, F. ^{[1
,2
]}

Lefort, A. ^{[3
]}

Lanternier, F. ^{[1
,2
]}

Bougnoux, M. -E. ^{[6
]}

Lortholary, O. ^{[1
,2
,4
,5
]}

机构：

[1] Ctr Infectiol Necker Pasteur, Paris, France

[2] Univ Paris 05, Hop Necker Enfants Malad, Serv Malad Infect & Trop, Ctr Infectiol Necker Pasteur, F-75743 Paris 15, France

[3] Univ Paris Diderot, Hop Beaujon, Serv Med Interne, F-92110 Clichy, France

[4] Ctr Natl Reference Mycol & Antifong, Inst Pasteur, F-75015 Paris, France

[5] CNRS, URA 3012, Paris, France

[6] Univ Paris 05, Hop Necker Enfants Malad, Serv Mycol & Parasitol, F-75015 Paris, France

来源：

REVUE DE MEDECINE INTERNE | 2011年 / 32卷 / 03期

关键词：

Candida spp; Invasive infection; Treatment; BLOOD-STREAM INFECTIONS; INTENSIVE-CARE-UNIT; HOSPITAL-ACQUIRED CANDIDEMIA; IN-VITRO SUSCEPTIBILITIES; LIPOSOMAL AMPHOTERICIN-B; RISK-FACTORS; FUNGAL-INFECTIONS; RANDOMIZED-TRIAL; CANCER-PATIENTS; EPIDEMIOLOGY;

D O I：

10.1016/j.revmed.2010.08.019

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Candida species is the fourth most common cause of bloodstream infection and is the leading cause of invasive fungal infection among hospitalized patients. Acute disseminated candidiasis remains a life-threatening disease that now occurs mainly in intensive care units hospitalized patients. Delay in treatment of Candida bloodstream infections could be minimized by the development of more rapid and sensitive diagnostic techniques for the identification of Candida bloodstream infections. Current guidelines for the management of invasive candidiasis recommend fluconazole or an echinocandin as the primary therapeutic option. The optimal choice of the antifungal agent should depend on local epidemiology, prior antifungal therapy and patient's characteristics. (c) 2010 Societe nationale francaise de medecine interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

引用

页码：173 / 180

页数：8

共 53 条

[1] Epidemiology and predictors of mortality in cases of Candida bloodstream infection:: Results from population-based surveillance, Barcelona, Spain, from 2002 to 2003 [J].

Almirante, B ;

Rodríguez, D ;

Park, BJ ;

Cuenca-Estrella, M ;

Planes, AM ;

Almela, M ;

Mensa, J ;

Sanchez, F ;

Ayats, J ;

Gimenez, M ;

Saballs, P ;

Fridkin, SK ;

Morgan, J ;

Rodriguez-Tudela, JL ;

Warnock, DW ;

Pahissa, A .

JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (04) :1829-1835

[2]

ANAISSIE EJ, 1995, 35 INT C ANT AG CHEM, P21

[3] Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility [J].

Arendrup, M. C. ;

Fuursted, K. ;

Gahrn-Hansen, B. ;

Schonheyder, H. C. ;

Knudsen, J. D. ;

Jensen, I. M. ;

Bruun, B. ;

Christensen, J. J. ;

Johansen, H. K. .

CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 (05) :487-494

[4] Detection of candidaemia in patients with and without underlying haematological disease [J].

Arendrup, M. C. ;

Bergmann, O. J. ;

Larsson, L. ;

Nielsen, H. V. ;

Jarlov, J. O. ;

Christensson, B. .

CLINICAL MICROBIOLOGY AND INFECTION, 2010, 16 (07) :855-862

[5] Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].

Ascioglu, S ;

Rex, JH ;

de Pauw, B ;

Bennett, JE ;

Bille, J ;

Crokaert, F ;

Denning, DW ;

Donnelly, JP ;

Edwards, JE ;

Erjavec, Z ;

Fiere, D ;

Lortholary, O ;

Maertens, J ;

Meis, JF ;

Patterson, TF ;

Ritter, J ;

Selleslag, D ;

Shah, PM ;

Stevens, DA ;

Walsh, TJ .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14

[6] Mortality and costs of acute renal failure associated with amphotericin B therapy [J].

Bates, DW ;

Su, L ;

Yu, DT ;

Chertow, GM ;

Seger, DL ;

Gomes, DRJ ;

Dasbach, EJ ;

Platt, R .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (05) :686-693

[7] Risk factors for candidal bloodstream infections in surgical intensive care unit patients: The NEMIS Prospective Multicenter Study [J].

Blumberg, HM ;

Jarvis, WR ;

Soucie, JM ;

Edwards, JE ;

Patterson, JE ;

Pfaller, MA ;

Rangel-Frausto, MS ;

Rinaldi, MG ;

Saiman, L ;

Wiblin, RT ;

Wenzel, RP .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (02) :177-186

[8]

BROSS J, 1989, AM J MED, V87, P614, DOI 10.1016/S0002-9343(89)80392-4

[9] Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? [J].

Charlier, C ;

Hart, E ;

Lefort, A ;

Ribaud, P ;

Dromer, F ;

Denning, DW ;

Lortholary, O .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (03) :384-410

[10] Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group [J].

De Pauw, Ben ;

Walsh, Thomas J. ;

Donnelly, J. Peter ;

Stevens, David A. ;

Edwards, John E. ;

Calandra, Thierry ;

Pappas, Peter G. ;

Maertens, Johan ;

Lortholary, Olivier ;

Kauffman, Carol A. ;

Denning, David W. ;

Patterson, Thomas F. ;

Maschmeyer, Georg ;

Bille, Jacques ;

Dismukes, William E. ;

Herbrecht, Raoul ;

Hope, William W. ;

Kibbler, Christopher C. ;

Kullberg, Bart Jan ;

Marr, Kieren A. ;

Munoz, Patricia ;

Odds, Frank C. ;

Perfect, John R. ;

Restrepo, Angela ;

Ruhnke, Markus ;

Segal, Brahm H. ;

Sobel, Jack D. ;

Sorrell, Tania C. ;

Viscoli, Claudio ;

Wingard, John R. ;

Zaoutis, Theoklis ;

Bennett, John E. .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) :1813-1821

← 1 2 3 4 5 6 →